ReviewThe American journal of case reports2026
Linezolid-Associated Triad of Acute Pancreatitis, Lactic Acidosis, and Hypoglycemia: A Rare Case Report and Literature Review.
Review in The American journal of case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND Linezolid is a widely used antibiotic with excellent oral bioavailability and broad-spectrum activity against resistant gram-positive organisms. However, its mitochondrial toxicity can result in serious adverse effects. We present a rare case of a triad of acute pancreatitis, lactic acidosis, and hypoglycemia associated with prolonged linezolid use - an underrecognized complication that can be life-threatening if not promptly identified. CASE REPORT A 59-year-old woman with end-stage renal disease on regular hemodialysis was treated with oral linezolid for a pulmonary infection complicated by a loculated pleural effusion. Three weeks into therapy, she presented to the emergency department with severe epigastric pain, nausea, and vomiting. Laboratory investigations revealed marked hyperlipasemia, high anion gap metabolic acidosis with elevated lactate levels, and relative hypoglycemia. Imaging and further laboratory workup ruled out other common causes of pancreatitis, including gallstones, alcohol use, hypertriglyceridemia, and drug interactions. In the absence of an alternative explanation, linezolid-induced mitochondrial toxicity was suspected as the underlying cause. The antibiotic was discontinued immediately. The patient showed rapid clinical and biochemical improvement with supportive management, including intravenous fluids and correction of metabolic derangements. CONCLUSIONS This case underscores the need for vigilance when prescribing linezolid, especially in patients with renal impairment, who are at higher risk of drug accumulation and toxicity. Clinicians should suspect linezolid-induced toxicity in patients presenting with new or unexplained gastrointestinal or metabolic symptoms during treatment. Early recognition and prompt discontinuation are necessary.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.